REL-1017
REL-1017-112
Phase 1 small_molecule completed
Quick answer
REL-1017 for Neuropathic Pain is a Phase 1 program (small_molecule) at RELMADA THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- RELMADA THERAPEUTICS, INC.
- Indication
- Neuropathic Pain
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed